Abstract Book

S914

ESTRO 37

Purpose or Objective To evaluate the efficacy of ZIVEREL ® for symptomatic relief in a retrospective cohort of patients with acute radiation-induced esophagitis receiving oncologic treatment with radiotherapy alone or radiochemotherapy. ZIVEREL ® is a new oral medical device composed of hyaluronic acid, chondroitin sulfate, and poloxamer 407. Radiation-induced esophagitis is a dose-limiting toxicity in oncologic treatment with radiotherapy or radiochemotherapy, and sometimes a limiting factor for treatment . Material and Methods Between February 2016-July 2017, we evaluated 41 patients (33 men and 8 women) treated with ZIVEREL ® , with a diagnosis of lung cancer (63.41%), gastric cancer (31.71%), and esophageal cancer (4.88%) who developed acute radiation-induced esophagitis (CTCAE grade 1 [60.98%] and grade 2 [39.02%]) during treatment with radiotherapy alone (36.59%) or radiochemotherapy (63.41%). The median age was 69 years (range, 38 to 90 years).

Purpose or Objective Exercise offers great potential as an adjunct therapy to reverse treatment-related side-effects and increase quality and quantity of life in people with cancer. In practice, uptake is poor due to community and medical belief that patients should rest during curative radiation cancer treatment especially if already undergoing chemotherapy and the overwhelming logistics of self- arranging training at other locations during daily radiation. Edith Cowan University (ECU) exercise medicine has a long experience successfully completing exercise studies in cancer patients, and were given an opportunity to co-locate a fully equipped training facility within the treatment section of a new Genesis radiation service, Shenton House. We report initial observational experience to demonstrate feasibility and benefits of this patient-centric approach and highlight areas for improvement. Material and Methods During the first 3-years, two training windows, on separate days, were available for patients undertaking long course curative-intent radiation treatment. Patients underwent aerobic and resistance exercise (60mins) either before or after their treatment sessions. At any given time up to a maximum of 12 patients were supervised by an exercise physiologist employing an ECUexercise medicine program for 6 weeks(12 sessions). A optional detailed offsite assessment was offered, where upper and lower body muscle strength (1-RM), physical function (6m usual and fast walk, 6m backwards walk, 400m walk, chair rise and stair climb) were assessed at baseline, end of resistance training and at 3 months follow-up. Compliance was defined as >8 attendances. Quality of life data was also collected Results 235 patients (mean age 60.1years) consented to participate at the site and of these patients 69 opted for the off-site testing assessments. Baseline demographics; age, sex, cancer site were not different between tested and not tested. Compliance>75%, non-attendance was attributed to chemo/radiation side effects, fatigue, family issues, other. Attendance for subsequent offsite testing was 44/69 at end of treatment and 27/69 at 3 months. No adverse events for exercise were identified. All functional assessments showed improvements at all time points. End of radiation improvements ( p <0.05) were observed for muscle strength (7.1-21.5%) and physical function (3.3-10.1%), with no significant adverse change in body composition. At 3 months, the improvement was maintained ( p <0.05) in leg press (21.4%) and seated row (9.1%) muscle strength, and for the 6m usual (9.2%), 6m backwards (18.5%), 400m walk (5%) and chair rise (9.8%) test. Conclusion We attribute the high participation and attendance levels to co-location and concurrent training time. Significant functional improvements followed, contrasting with expected declines from rest therapy. We suggest this approach is workable and effective and introduces patients to Exercise medicine and longer-term health benefits beyond those described here. EP-1704 How efficacious is Ziverel® for symptomatic relief of acute radiation-induced esophagitis? E. Carrasco-Esteban 1 , F. López-Campos 1 , S. Sastre- Gallego 1 , P. Barrionuevo Castillo 1 , M. Martín-Martín 1 , R. Hernanz-de Lucas 1 , C. Vallejo-Ocaña 1 , S. Sancho-García 1 1 Ramon y Cajal University Hospital, Radiation Oncology, Madrid, Spain

Results Of the total number of patients, 38 (92.68%) experienced an improvement of their symptoms; 13 of these patients (34.21%) had previously received support treatment, according to usual clinical practice, compared with 3 patients (7.32%) in whom ZIVEREL ® did not lead to an improvement in symptoms. ZIVEREL ® was prescribed as initial treatment (41.46%), after initiation of support treatment (34.15%), or together with support treatment (24.39%). Of the 41 patients treated, 39 patients (95.12%) completed the oncologic treatment satisfactorily, and it was necessary to interrupt oncologic treatment in only 2 cases (4.88%) of total number of patients. Conclusion ZIVEREL ® is well tolerated and plays a key role in the symptomatic relief of radiation- induced esophagitis resulting from oncologic treatment. EP-1705 Radiotherapy: a promising alternative treatment for painful osteoarticular degenerative diseases. B. Alvarez 1 , A. Montero Luis 1 , A. Acosta 1 , E. Sanchez 1 , R. Ciervide 1 , X. Chen 1 , J. Valero 1 , M. Garcia-Aranda 1 , F. Aramburu 2 , E. Calvo 2 , O. Hernando 1 , M. Lopez 1 , S. Rodriguez 2 , R. Alonso 1 , P. Garcia de la Peña 2 , C. Rubio 1 1 Hospital Universitario Madrid Sanchinarro - Grupo Hospital de Madrid, Radiation Oncology, Madrid, Spain 2 Hospital Universitario Madrid Sanchinarro - Grupo Hospital de Madrid, Reumatology, Madrid, Spain